Search

Your search keyword '"Rovira, Ana"' showing total 4 results
Start Over Author "Rovira, Ana" Journal oncoimmunology
4 results on '"Rovira, Ana"'

1. Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer

Author

Hardy-Werbin, Max, primary, Rocha, Pedro, additional, Arpi, Oriol, additional, Taus, Álvaro, additional, Nonell, Lara, additional, Durán, Xavier, additional, Villanueva, Xavier, additional, Joseph-Pietras, Deborah, additional, Nolan, Luke, additional, Danson, Sarah, additional, Griffiths, Richard, additional, Lopez-Botet, Miguel, additional, Rovira, Ana, additional, Albanell, Joan, additional, Ottensmeier, Christian, additional, and Arriola, Edurne, additional

Published
2019
Full Text
View/download PDF

3. Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors.

Author

Galindo, Miguel, Navarro, Judith, Yélamos, José, Albanell, Joan, Rovira, Ana, Rojo, Federico, and Oliver, Javier

Subjects
CANCER treatment, THERAPEUTIC use of monoclonal antibodies, POLY(ADP-ribose) polymerase, EPIDERMAL growth factor receptors, DNA damage
Abstract

Monoclonal antibodies (mAbs) have become a successful therapeutic approach in cancer. However, some patients do not achieve long-term clinical benefit and most mAbs only exert modest effects as monotherapies. Therefore, combinations with chemotherapy are currently being investigated. Emerging studies have shown a synergistic therapeutic effect of PARP inhibitors and mAbs in cancer. PARP enzymes catalytically cleave β-NAD+and transfer the ADP-ribose moiety to acceptor proteins, modifying their function. In here, we update recent data about the therapeutic effect of the combination of PARP inhibitors with mAbs in cancer treatment and discuss the molecular mechanisms involved in this synergy. [ABSTRACT FROM PUBLISHER]

Published
2016
Full Text
View/download PDF

4. Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors

Author

Yélamos, José, Galindo, Miguel, Navarro, Judith, Albanell, Joan, Rovira, Ana, Rojo, Federico, and Oliver, Javier

Abstract

ABSTRACTMonoclonal antibodies (mAbs) have become a successful therapeutic approach in cancer. However, some patients do not achieve long-term clinical benefit and most mAbs only exert modest effects as monotherapies. Therefore, combinations with chemotherapy are currently being investigated. Emerging studies have shown a synergistic therapeutic effect of PARP inhibitors and mAbs in cancer. PARP enzymes catalytically cleave β-NAD+and transfer the ADP-ribose moiety to acceptor proteins, modifying their function. In here, we update recent data about the therapeutic effect of the combination of PARP inhibitors with mAbs in cancer treatment and discuss the molecular mechanisms involved in this synergy.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results